Gold Rally Could Send this Stock Soaring 🚀

[Image](www.elitetrade.club) Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. Today is Wednesday, January 25th. I hope you have a great day. Now, let's get ready to trade! Markets 📈 The Dow edged out a 0.3% gain on Tuesday, while the rest of the large-cap benchmarks fell. The S&P 500 posted a small fractional loss, while the Nasdaq and Russell 2K both fell 0.2%. Today, futures are heading lower in early-morning trading. S&P 500 contracts are currently down 0.7%. Sponsored [Gold Rally Could Send this Stock Soaring 🚀]( An under-the-radar stock could be the #1 play to cash in on gold's recent boom. This company just performed an initial analysis at one of its sites, and it looks like it might have hit the jackpot. With gold prices soaring, this jaw-dropping new discovery could be extremely valuable, and the market is already taking notice. [Get the Ticker & See Why This Stock Could Explode]( Premarket Highlights 🔎 💰 Jittery Investors Move to Cash: New data shows inflows to money-market funds are at their highest levels since 2020, a sign that uncertain market conditions are driving more investors to flee for safety. What to Watch Today 👀 Another Big Day for Earnings It's another big day for earnings. Yesterday's slate of reports sent the market lower after Microsoft reported slowing sales growth, and 3M announced job cuts in response to a sales slowdown. Today's docket includes powerhouses like Tesla, IBM, and Boeing. Right now, the market seems to be on a downward trajectory for the day, but a few upbeat reports could easily shift investor sentiment. Major Earnings 💰 Abbott Laboratories [ABT] ... AM Nextera Energy, Inc. [NEE] ... AM AT&T Inc. [T] ... AM Boeing Company (The) [BA] ... AM Elevance Health, Inc. [ELV] ... AM Automatic Data Processing, Inc. [ADP] ... AM Tesla, Inc. [TSLA] ... PM International Business Machines Corporation [IBM] ...PM Servicenow, Inc. [NOW] ... PM CSX Corporation [CSX] ... PM Economy 🏗 - None Running Hot 🔥 Gainers - Inpixon [INPX] >> +26.2% - Plutonian Acquisition [PLTNU] >> +24.0% - Aridis Pharma [ARDS] >> +21.4% Decliners - Grom Social [GROM] >> (29.6%) - Waitr Holdings [ASAP] >> (23.6%) - Axcella Health [AXLA] >> (21.6%) News Corp B [NWS] - Last Close: $19.91 News Corp is moving on reports of a key asset sale. On Tuesday evening, the media giant confirmed it's talking with CoStar Group [CSGP] about a potential sale of Move Inc, the operator of Realtor.com. News Corp says a potential deal would enhance the value of its digital real estate services segment. However, the company specified that there's no assurance the talks will result in a deal. NWS is leading the S&P 500 with a 4.6% gain in today's premarket. My Take: Nice little premarket bump for NWS, but the stock could see more gains if the talks result in a deal. This could be worth keeping an eye on in the days ahead. Sonoma Pharmaceuticals [SNOA] - Last Close: $1.20 A premarket announcement is boosting shares of Sonoma Pharma. This morning, the pharma firm said its Microcyn Rx products have received a Distribution and Pricing Agreement (DAPA) from the Defense Logistics Agency. The DAPA agreement allows the company's partner, EMC Pharma, to enter into distribution deals with federal customers. The U.S. federal government is the world's largest purchaser of goods & services, and the company believes the deal is a "major step." SNOA is up 67.5% on the news, making it one of this morning's top-performing stocks. My Take: SNOA's federal deal could boost its revenues in the months ahead, but we won't know its true top-line impact for quite some time. Cidara Therapeutics [CDTX] - Last Close: $0.9281 Cidara Therapeutics just made a big announcement. The biotech firm announced an FDA advisory panel has recommended approval of rezafungin for the treatment of candidemia and invasive candidiasis. Cidara said the approval was based on clinical data from a global ReSTORE Phase 3 trial and supported by its STRIVE Phase 2 trials. The FDA is not bound by the Advisory Committee's recommendation, but generally gives it significant consideration when making its decision. News of the FDA ruling sent CDTX to a 33.6% premarket gain. My Take: Sounds like CDTX's drug is on course for approval, but how much of that good news is already priced into the stock as of today's rally? There could be some opportunity to sneak in on a pull-back, just be careful you don't get caught holding the bag. . First Wave BioPharma [FWBI] - Last Close: $4.42 First Wave Bio is rallying on news of a patent filing. The biotech firm said it filed a U.S. Provisional Patent application on the composition of matter improvements to enhance adrulipase's delayed release profile. The filing adds to First Wave's growing portfolio of intellectual property governing adrulipase. The company has pending patent applications on the drug's formula, methods of use, and the utilization of enteric formulations in adrulipase's delivery. FWBI jumped 26.7% after announcing the new patent application. My Take: FWBI could get another boost if this patent application is approved. However, this is a very tiny-float stock with a high short rate of 8.67%, so there could be some targeted market manipulation in play here. That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... If you're on the hunt for a new broker, check out our preferred partner, moomoo! You can [get 15 free stocks]( worth up to $2,000 each if you join the moomoo App now. [Click here to get started.]( P.P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 or [click here]( to sign up now and get our watchlists sent directly to your phone! Or text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](